Author: Mitchell Gaydash
IIVS Posters – SOT 2023 Annual Meeting
March 31, 2023IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented. Application of a Performance Characterization Protocol for the Assessment of Normal and Diseased Cryopreserved Human Precision-Cut Lung Evaluation and Transferability of a New Approach Methodology to Address Photoallergy Evaluation of Complex Compounds in the UV-Vis Absorption Spectra General Behaviors of Surfactants in the Bovine Corneal Opacity and Permeability Modifications in the RhE Phototoxicity Assay to Evaluate Long-Lasting Cosmetic Products Optimization of an In Vitro Preclinical Screening...
62nd Annual Meeting of the Society of Toxicology
March 14, 2023IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834. ...
IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
March 9, 2023The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics and other substances without the use of animal testing....
March 2023 Newsletter
March 1, 2023IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations....
Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters
February 23, 2023The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting in vitro assays, to assess potential toxicity within and across tobacco and various next generation nicotine and tobacco products (NGPs), including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS). The third workshop (24–26 February 2020) summarised the key challenges and made recommendations concerning appropriate methods of test article generation and cell exposure from...
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2
February 16, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1
February 7, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....
IIVS Leadership Newsletter
February 3, 2023Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance of non-animal approaches worldwide....
November 2022 Newsletter
November 10, 2022IIVS is pleased to announce the appointment of Amanda Ulrey to our Board of Directors. As a 20-year veteran at IIVS, Mandy is currently Vice President of Business Operations and where she is primarily responsible for instituting quality management systems and regulatory compliance throughout the organization, as well as administering IIVS’ business-to-business certification in Good In Vitro Method Practices (GIVIMP)....
Experimental Toxicology and Ecology of BASF receives certification for Good In Vitro Method Practices
October 19, 2022Ludwigshafen, Germany and Gaithersburg, Maryland, USA – October 19, 2022 – The Institute for In Vitro Sciences (IIVS) certified BASF’s Experimental Toxicology and Ecology for Good In Vitro Method Practices (GIVIMP) based on the guidance document published in 2018 by the Organization of Economic Cooperation and Development (OECD). The GIVIMP document provides principles in quality management which, when implemented, serve to increase the quality and confidence in data generated by in vitro test methods. ...